Nugenerex Immuno-Oncology Employees 2024

Nugenerex Immuno-Oncology has 0 undefined employees this year.

Compared to the previous year, Nugenerex Immuno-Oncology had 0% more employees.

The number of employees has a direct impact on the efficiency and productivity of Nugenerex Immuno-Oncology. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

The number of employees can also have an impact on investors of Nugenerex Immuno-Oncology, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

An increase in equity of Nugenerex Immuno-Oncology can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

A reduction in equity of Nugenerex Immuno-Oncology can impair its financial stability and decrease its ability to fulfill future investments and obligations.

Some factors that can influence the equity of Nugenerex Immuno-Oncology include, among others, revenue development, profit and loss statement, dividend payments, and investments.

The equity of Nugenerex Immuno-Oncology is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

The number of employees at Nugenerex Immuno-Oncology can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

In recent years, the number of employees at Nugenerex Immuno-Oncology has changed by NaN.

Nugenerex Immuno-Oncology currently has 0 undefined employees.

The number of employees is important for investors of Nugenerex Immuno-Oncology as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

To change the number of employees, Nugenerex Immuno-Oncology can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

The current dividend yield of Nugenerex Immuno-Oncology is .

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

Nugenerex Immuno-Oncology is assigned to the '-' sector.

To receive the latest dividend of Nugenerex Immuno-Oncology from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

The last dividend was paid out on 9/30/2024.

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

The dividends of Nugenerex Immuno-Oncology are distributed in USD.